transmembrane protein 132DGenealiases: MOLT · PPP1R153
Q-omics provides the consensus-scored TMEM132D profile across patient tissues and cancer cell-line models. TMEM132D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM132D is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TMEM132D RNA expression shows 15,043 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where TMEM132D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM132D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM132D survival associations across molecular data types. TMEM132D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM132D RNA expression–survival associations across cancer types. High TMEM132D expression shows unfavorable associations in ESCA and DLBC, but favorable associations in KIRC, KIRP, LUAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM132D RNA expression.
This table summarizes TMEM132D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM132D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM132D shows lower tumor expression in COAD, KICH, LUSC, LUAD and UCEC and higher tumor expression in THCA. The COAD box plot shows higher TMEM132D RNA expression in normal versus tumor tissue (log2 FC = −0.238, t-test p < 0.001).
This table shows molecular features associated with TMEM132D in patient tissues and cancer cell lines. In patient samples, TMEM132D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM132D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
